10320 Camino Santa Fe, Suite G
San Diego, CA 92121
Tel: 858.875.1900 Fax: 858.875.1999

RARS antibody - C-terminal region

Rabbit Polyclonal Antibody
Catalog # AI14917

Product Information

Application	WB
Primary Accession	P54136
Other Accession	NM_002887, NP_002878
Reactivity	Human, Mouse, Rat, Rabbit, Zebrafish, Dog, Guinea Pig, Horse, Bovine
Predicted	Human, Mouse, Rabbit, Zebrafish, Pig, Dog, Horse
Host	Rabbit
Clonality	Polyclonal
Calculated MW	75379

Additional Information

Gene ID	5917
Alias Symbol	ArgRS, DALRD1, MGC8641
Other Names	Arginine--tRNA ligase, cytoplasmic, 6.1.1.19, Arginyl-tRNA synthetase, ArgRS, RARS
Format	Liquid. Purified antibody supplied in 1x PBS buffer with 0.09% (w/v) sodium azide and 2% sucrose.
Reconstitution & Storage	Add 50 ul of distilled water. Final anti-RARS antibody concentration is 1 mg/ml in PBS buffer with 2% sucrose. For longer periods of storage, store at 20°C. Avoid repeat freeze-thaw cycles.
Precautions	RARS antibody - C-terminal region is for research use only and not for use in diagnostic or therapeutic procedures.


Protein Information

Name	RARS1 (HGNC:9870)
Synonyms	RARS
Function	Forms part of a macromolecular complex that catalyzes the attachment of specific amino acids to cognate tRNAs during protein synthesis (PubMed:25288775). Modulates the secretion of AIMP1 and may be involved in generation of the inflammatory cytokine EMAP2 from AIMP1 (PubMed:17443684).
Cellular Location	Cytoplasm. Cytoplasm, cytosol

References

Girjes A.A.,et al.Gene 164:347-350(1995).
Kalnine N.,et al.Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases.
Ota T.,et al.Nat. Genet. 36:40-45(2004).
Suzuki Y.,et al.Submitted (APR-2005) to the EMBL/GenBank/DDBJ databases.
Gevaert K.,et al.Nat. Biotechnol. 21:566-569(2003).

Images



WB Suggested Anti-RARS Antibody Titration: 1.0 µg/ml
Positive Control: 721_B Whole CellRARS is supported by BioGPS gene expression data to be expressed in 721_B

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.